Anita D'Souza, MD

Associate Professor

view physician profile

Locations

Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Anita D’Souza, MD, MS completed medical school in Goa Medical College, India where she graduated at the top of her class and was voted Best Medical Graduate. She completed her Hematology and Medical Oncology fellowship at the Mayo Clinic, Minnesota.

Research Interests

Dr. D'Souza's clinical and research work is focused on plasma cell cancers (e.g. multiple myeloma, AL amyloidosis, POEMS syndrome, Waldenstrom Macroglobulinemia) and the use of hematopoietic cell transplantation to treat these diseases. She serves as a scientific director of the Plasma Cell Disorders and Adult Solid Tumors working committee in the Center for International Blood and Marrow Transplant Research (CIBMTR). She is principal investigator on clinical trials in amyloidosis and multiple myeloma. She is a recipient of the 2016 KL2 Career Development Award from the Clinical and Translational Science Institute. Dr. D’Souza is board certified in Internal Medicine, Hematology and Medical Oncology.

Writing and Erasing O-GlcNAc on Casein Kinase 2 Alpha Alters the Phosphoproteome.

(Schwein PA, Ge Y, Yang B, D'Souza A, Mody A, Shen D, Woo CM.) ACS Chem Biol. 2022 May 20;17(5):1111-1121 PMID: 35467332 04/26/2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.

(Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N, D'Souza A.) Blood Adv. 2022 05 04 PMID: 35507742 05/05/2022
MGIP, MGUS, and the PROMISE of meaning in small things.

(D'Souza A, Costa LJ.) Lancet Haematol. 2022 05;9(5):e315-e317 PMID: 35344690 03/29/2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.

(Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C.) Am J Hematol. 2022 Apr 26 PMID: 35472167 SCOPUS ID: 2-s2.0-85129190892 04/27/2022
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.

(Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P.) Blood Adv. 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021
Nutrition perceptions, needs and practices among patients with plasma cell disorders.

(Malik MA, Sweeney NW, Jafri M, Derkach A, Chmielewski C, Adintori PA, Mailankody S, Korde N, Tan CR, Hassoun H, Hultcrantz M, Hillengass J, McCann SE, Iyengar N, Usmani S, Giralt SA, Landgren O, van den Brink MRM, Ahlstrom JM, Lesokhin AM, D'Souza A, Chimonas S, Shah UA.) Blood Cancer J. 2022 04 20;12(4):70 PMID: 35443718 PMCID: PMC9021216 04/22/2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.

(Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M.) Transplant Cell Ther. 2022 Apr 18 PMID: 35447374 04/22/2022
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients.

(Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.) Cancer Cell. 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022
Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.

(Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P.) Blood Cancer J. 2022 02 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 02/26/2022
Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA.

(Lin M, Pezzin LE, Mohamedi A, Kansagra A, D'Souza A.) J Racial Ethn Health Disparities. 2022 Feb 01 PMID: 35106741 02/03/2022
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

(Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS.) J Clin Oncol. 2021 Dec 13:JCO2101935 PMID: 34898239 12/14/2021